Drug intelligence / Profile preview

TMC589354

Development stage: Unknown
Lead developer: Johnson & Johnson
Modality: Small Molecules
Administration: Oral

Overview

TMC589354 is an investigational small molecule developed by Johnson & Johnson as part of the PEPI family of compounds. It was designed not for direct antiviral activity, but to enhance the pharmacokinetic profile of other drugs, specifically HIV-1 protease inhibitors such as TMC310911. In clinical studies, TMC589354 was evaluated for its safety, tolerability, and ability to boost plasma levels of co-administered drugs in healthy volunteers. The compound reached Phase 1 clinical trials but development has since been discontinued[1][3][4][5].

Beyond the preview

Go deeper on TMC589354.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TMC589354.

Explore the full profile